Remove Clinical Research Remove Download Remove Trials
article thumbnail

Emerging Trends in Clinical Trial Design

PPD

The COVID-19 pandemic rapidly accelerated the adoption of hybrid and decentralized clinical trial (DCT) models. At the end of 2022, the PPD clinical research business of Thermo Fisher Scientific surveyed key leadership and staff on the frontline of clinical trial execution across the industry.

article thumbnail

Key Trends Drug Developers Need to Know to Succeed

PPD

From adapting to complex new trial designs to embracing cutting-edge technologies, staying ahead requires a deep understanding of the current landscape. Drug development The rising cost of clinical trials is the top challenge this year, due to increasingly complex protocol designs and difficult patient recruitment.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How FSP Solutions Support Risk-Based Methodologies and Tech Innovation in Clinical Operations

PPD

In the past, these developers mostly used in-house resources for their clinical monitoring and site management capabilities, whereas today they often prefer functional service provider (FSP) or full-service outsourcing (FSO) models, or a hybrid of the two, to ensure on-time and on-budget delivery of clinical operations.

article thumbnail

Optimizing Clinical Trials: Getting the Right Results by Keeping it Real

Fierce BioTech

Optimizing Clinical Trials: Getting the Right Results by Keeping it Real Discover how RWD can transform your approach to clinical trial protocol optimization, patient identification, and site selection in this survey of clinical research leaders by Flatiron Health. Download now.

article thumbnail

The Real Cost of Complexity: What Every Drug Developer Needs to Know

PPD

The drug development industry faces rising costs and increasingly complex protocols as top challenges, with 49% of developers citing costs as their primary concern and 39% pointing to protocol complexity as a key hurdle, according to a recent survey of 150 drug developers worldwide by the PPD clinical research business of Thermo Fisher Scientific.

article thumbnail

Five Predictions for the Biopharma and Biotech Industries in 2024

PPD

These shifts are a prelude to further change and progress in the clinical trial landscape in 2024. To get a pulse on the changing industry, the PPD clinical research business of Thermo Fisher Scientific surveyed 150 biotech and biopharma leaders for the second year in a row to illuminate industry trends, challenges and sentiments.

article thumbnail

New Report Reveals Trends, Opportunities in Drug Development

PPD

As the clinical trial landscape evolves, drug developers are faced with novel challenges and changes in study recruitment, trial size and structure, and more. Decentralized Trials Digital and decentralized clinical trials  (DCTs) continue to expand and have become a standard solution for drug developers.